Business Context and Reporting Period
Company: Alzamend Neuro, Inc. (ALZN)
Filing Type: Form 10-Q (Unaudited)
Period Ended: July 31, 2026
Business Overview: Alzamend is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. The company has two primary product candidates: AL001 (a lithium ionic cocrystal) and ALZN002 (an immunotherapy vaccine). The company has not generated any product revenue to date and relies on equity and debt financing.
Key Financial Metrics
| Metric | Q2 2026 (Three Months Ended July 31) | Q2 2025 (Three Months Ended July 31) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,027,002) | $(2,702,684) |
| Loss Per Share (Basic & Diluted) | $(0.68) | $(1.28) |
| Cash and Cash Equivalents (End of Period) | $7,591,444 | $5,620,872 |
| Working Capital | $5,515,499 | Filing text does not provide a clear value for Q2 2025 |
| Total Assets | $8,542,061 | Filing text does not provide a clear value for Q2 2025 |
| Total Liabilities | $2,739,381 | Filing text does not provide a clear value for Q2 2025 |
| Stockholders' Equity | $5,802,680 | $5,343,440 |
Cash Flow Summary (Three Months Ended July 31, 2026):
- Net cash used in operating activities: $(1,138,517)
- Net cash provided by financing activities: $8,019,272 (primarily from issuance of Series D Preferred Stock and Common Stock)
- Net increase in cash: $6,880,755
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 12% to $3.03 million from $2.70 million.
- Research and Development (R&D): Decreased 38% to $1.09 million, driven by a $732,000 reduction in clinical trial fees as the Phase IIA brain imaging study concluded in the prior year.
- General and Administrative (G&A): Increased 102% to $1.94 million. This was primarily due to a $1.04 million increase in professional fees, largely attributed to legal costs associated with a lawsuit against a former contract research organization (Biorasi).
- Capital Structure: The company raised significant capital in the quarter.
- Sold 7,500 shares of Series D Convertible Preferred Stock for $7.5 million.
- Sold 569,684 shares of Common Stock via an At-the-Market (ATM) offering for $669,272.
- Liquidity: Cash balances increased from $710,689 at the beginning of the period to $7,591,444 at the end of the period.
Outlook, Risks, and Management Commentary
Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least one year following the issuance of these financial statements. The company expects to continue incurring net losses and will require additional financing to fund operations and clinical trials.
Clinical Pipeline Updates:
- AL001: Phase II imaging trials with Massachusetts General Hospital (MGH) are ongoing. Topline pharmacokinetic data was reported in March 2026 showing superior brain penetration compared to standard lithium carbonate. A Phase II trial for Bipolar Disorder (BD) was initiated in March 2026, with topline data expected in Q4 2026. Trials for MDD and PTSD are expected to commence in Q4 2026, followed by Alzheimer's in Q1 2027.
- ALZN002: The Phase I/IIA clinical trial was delayed due to the termination of the contract with Biorasi. The company is seeking a replacement CRO and does not expect to restart the trial until Q2 2027.
Internal Controls: The company disclosed a material weakness in internal control over financial reporting due to insufficient resources in the accounting department, restricting the ability to perform sufficient reviews of manual journal entries and account reconciliations. Remediation efforts are underway.
Legal Proceedings: The company is engaged in litigation against Biorasi, LLC, regarding the termination of their contract. The trial is expected to be completed by the end of December 2026.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $7.6 million cash balance against the projected burn rate, given the "substantial doubt" regarding going concern status.
- Series D Terms: Review the conversion mechanics of the Series D Preferred Stock, specifically the "Floor Price" ($0.2668) and "Maximum Price" ($2.00) which could lead to significant dilution.
- ALZN002 Timeline: Confirm the status of the new CRO engagement and the feasibility of restarting the ALZN002 trial in Q2 2027.
- Legal Exposure: Monitor the outcome of the lawsuit against Biorasi and the associated legal costs impacting G&A expenses.
- Internal Controls: Assess the progress of remediation for the material weakness in financial reporting controls.